This week in drug discovery (27-31 May)
News round-up for 27-31 May by DDW Senior Digital Content Editor Diana Spencer.
The selected news highlights this week report breakthrough findings from early phase research and development, mainly preclinical studies and Phase I clinical trials, including a drug that can prevent sepsis deaths, a microbiome based immuno-oncology candidate, and a plant-based therapy for diarrhoea.
The top stories:
New drug could prevent sepsis-related organ failure
A new drug could prevent sepsis-related organ failure and death by restoring the health of a patient’s blood vessels. Researchers from The University of Queensland and the Queensland Children’s Hospital (QCH) have successfully tested the first-in-class drug in mice.
Microbiome therapeutic shows potential in refractory cancers
Biomica has revealed encouraging initial findings from an ongoing Phase I clinical trial of its microbiome-based immuno-oncology candidate, BMC128, in combination with an anti-PD1 immune checkpoint inhibitor.
Plant-based drug reduces symptoms in functional diarrhoea patients
This World Digestive Health Day, Napo Pharmaceuticals has announced positive results of a third-party, investigator-initiated study of crofelemer, Napo’s novel plant-based prescription drug.
Dual receptor beta-agonist promotes healthy weight loss
A new research paper has validated the mechanism of action of the Atrogi’s first-in-class, small molecule, ATR-127, in combating obesity and metabolic complications.
Drug candidate for apathy enters Phase I trials
Swedish company IRLAB Therapeutics has initiated a Phase I study of IRL757, its drug candidate for apathy – a condition associated with Parkinson’s disease and other CNS diseases.
